header website Rosalie Luiten


About me


My research



Science & Society



My publications | Book Chapters | Patents | Publications about my research

My publications

54. Teulings HE, Lommerts JE, Wolkerstorfer A, Nieuweboer-Krobotova L, Luiten RM, Bekkenk MW, Vander Veen JP. Vitiligo-like depigmentations as first sign of melanoma; a retrospective case series from a tertiary vitiligo centre. Br J Dermatol. 2016 Jun 7. In press

53. Komen L, Vrijman C, Prinsen CA, van der Veen JP, Luiten RM, Wolkerstorfer A. Optimising size and depth of punch grafts in autologous transplantation of vitiligo and piebaldism: a randomised controlled trial. J Dermatolog Treat. 2016 Jun 16:1-6.

52. van den Boorn JG, Jakobs C, Hagen C, Renn M, Luiten RM, Melief CJ, Tüting T, Garbi N, Hartmann G, Hornung V. Inflammasome-Dependent Induction of Adaptive NK Cell Memory. Immunity. 2016 Jun 21;44(6):1406-21.

51. H.E. Teulings, E. Ceylan, M. Overkamp, C. Vrijman, J.D. Bos, T.E. Nijsten, A. Wolkerstorfer, R.M. Luiten, J.P.W. van der Veen. Non-segmental vitiligo disease duration and female sex are associated with comorbidity and disease extent; A retrospective analysis in 1307 patients older than 50 years. Br J Dermatol. 2016 Apr 4. in press

50. J. Klarquist, J.M. Eby, S.W. Henninga, M. Lib, D.A. Wainwright, W. Westerhof, R.M. Luiten, M.I. Nishimura, I.C. Le Poole. Functional cloning of a gp100-reactive T cell receptor from vitiligo patient skin. Pigment Cell Melanoma Research 2016, in press

49. L. Komen, C. Vrijman, E.P. Tjin, G. Krebbers, M.A. de Rie, R.M. Luiten, J.P.W. van der Veen, A. Wolkerstorfer. Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: A randomized controlled pilot study. J Am Acad Dermatol. 2015 Jul;73(1):170-2

48. K. Szegedi, R. Lutter, P.C. Res, J.D. Bos, R.M. Luiten, S. Kezic S, M.A. Middelkamp-Hup. Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol. 2015; in press.

47. A. Kammeijer, R.M. Luiten. Oxidation events and skin aging. Ageing Research Reviews 2015; 21:16-29.

46. H.E. Teulings, J. Limpens, S.N. Jansen, A.H. Zwinderman, J.B. Reitsma, Ph.I. Spuls, R.M. Luiten. Vitiligo-like depigmentation in stage III-IV melanoma patients receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Onc. 2015; 33(7):773-781.

45. E.P.M. Tjin, G.Krebbers, K.J. Meijlink, W. van de Kasteele, E.H. Rosenberg, Joyce Sanders, P.M. Nederlof, B.A. van de Wiel, J.B.A.G. Haanen, C.J.M. Melief, F.A. Vyth-Dreese, R.M. Luiten. Immune escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. Global Medical Discovery 2014, in press

44. E.P.M. Tjin and R.M. Luiten. Tumor-infiltrating T-cells: important players in clinical outcome of advanced melanoma patients. OncoImmunology 2014; 13(3): e954862.

43. H.E. Teulings, K.J. Willemsen, I. Glykofridis, G. Krebbers, L. Komen, M.W Kroon, E. H. Kemp, A. Wolkerstorfer, J.P.W. van der Veen, R.M. Luiten, E.P.M. Tjin. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo. Pigment Cell Melanoma Res., 2014; 27(6):1086-1096.

42. K. Webb; J. Eby, V. Hariharan, C. Hernandez, R.M. Luiten, I.C. Le Poole. Enhanced Bleaching Treatment: Opportunities for Immune-Assisted Melanocyte Suicide in Vitiligo. Exp Dermatol, 2014; 23(8):529-533.

41. E.P.M. Tjin, G.Krebbers, K.J. Meijlink, W. van de Kasteele, E.H. Rosenberg, Joyce Sanders, P.M. Nederlof, B.A. van de Wiel, J.B.A.G. Haanen, C.J.M. Melief, F.A. Vyth-Dreese, R.M. Luiten. Immune escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. Cancer Immunology Research 2014; 2(6):538-546.

40. M.W. Kroon, C. Vrijman, C. Chandeck, B.S Wind, A. Wolkerstorfer, R.M. Luiten, J.D. Bos, R.B. Geskus, P. van Trotsenburg, J.P.W van der Veen. High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr. 2013;79:137-44.

39. H.E. Teulings, E. P.M. Tjin , K.J. Willemsen, G. Krebbers , C.J. van Noesel, E.H. Kemp, L. Nieuweboer-Krobotova, J.P.W. van der Veen, R.M. Luiten. Radiation induced melanoma-associated-leukoderma, systemic anti-melanoma immunity and disease-free survival in an advanced-stage melanoma patient: A case report and immunological analysis. Br J Dermatol. 2013, in press

38. H.E. Teulings, M. Overkamp, E. Ceylan, L. Nieuweboer-Krobotova, J.D. Bos, T. Nijsten, A. Wolkerstorfer, R.M. Luiten*, J.P.W. van der Veen*. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013; 168(1):162-171. * authors contributed equally

37. C. Vrijman, D. Hosseinpour, J.G.Bakker, A. Wolkerstorfer, J.D Bos, J.P.W. van der Veen, R.M Luiten. Provoking factors including chemicals in Dutch vitiligo patients. Br J Dermatol. 2012, in press

36. C. Vrijman, M.W. Kroon, J. Limpens , M.M. Leeflang, R.M. Luiten, J.P. van der Veen, A. Wolkerstorfer, Ph.I. Spuls. The prevalence of thyroid disease in vitiligo patients: a systematic review.Br J Dermatol. 2012, in press

35. P. Weder, T. N.M. Schumacher, H. Spits, R.M. Luiten. Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes. Results in Immunology 2012, May 17, 88-96.

34. Y. Jin, S.A. Birlea, P.R. Fain, T.M. Ferrara, S. Ben, S.L. Riccardi, J.B. Cole, K. Gowan, P.J. Holland, D.C. Bennett, R.M. Luiten, A. Wolkerstorfer, J.P. van der Veen, A. Hartmann, S. Eichner, G. Schuler, N. van Geel, J. Lambert, E.H. Kemp, D.J. Gawkrodger, A.P. Weetman, A. Taïeb, T. Jouary, K. Ezzedine, M.R. Wallace, W.T. McCormack, M. Picardo, G. Leone, A. Overbeck, N.B. Silverberg, R.A. Spritz. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet. 2012 May 6, in press

33. K. Szegedi, A.E. Kremer, S. Kezic, M.B.M. Teunissen, J.D. Bos, R.M. Luiten, P.C. Res, M.A. Middelkamp-Hup. Increased frequencies of IL-31 producing T cells are found in Chronic Atopic Dermatitis skin. Exp. Derm. 2012, in press

32. V.Stroobant, N. Demotte, R.M. Luiten, R.M. Leonhardt, P. Cresswell, A.Bonehill, A. Michaux, W. Ma, A. Mulder, B.J. Van den Eynde, P. van der Bruggen, N. Vigneron. Exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be restored by acid treatment or fixation of target cells. Eur. J. Immunol. 2012, in press.

31. M.W. Kroon, E. H. Kemp, B.S. Wind, G. Krebbers, J.D. Bos, D.J. Gawkrodger, A. Wolkerstorfer, J.P.W. van der Veen, R.M. Luiten. Melanocyte antigen- specific antibodies can not be used as markers for recent disease activity. J. Eur. Acad. Dermatol. Venereol. 2012, in press.

30. M.W. Kroon, I.C. Joore, B.S. Wind, M.A. Leloup, A. Wolkerstorfer, R.M. Luiten, J.D. Bos, R.B. Geskus, J.P.W. van der Veen. Low yield of routine screening for thyroid dysfunction in asymptomatic vitiligo patients. Br. J. Dermatol. 2012, 166(3):532-538.

29. R. Speeckaert, N.van Geel, R.M. Luiten, M. Van Gele, M. Speeckaert, J. Lambert, K. Vermaelen, E.P.M. Tjin, L. Brochez. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res, 2011, 31(11):3697-703.

28. N. van Geel, R. Speeckaert, I. Mollet, S. De Schepper, J. De Wolf, E.P. Tjin, R.M. Luiten, J. Lambert, L.  Brochez. In vivo vitiligo induction and therapy model : double blind, randomized clinical trial. Pigment Cell Melanoma Res. 2012, 25(1):57-65.

27. E.P. Tjin, D Konijnenberg, G. Krebbers, H. Mallo, J.W. Drijfhout, K.L. Franken, C.M. van der Horst, J.D. Bos, O.E. Nieweg, B.B. Kroon, J.B. Haanen, C.J. Melief, F.A. Vyth-Dreese, R.M. Luiten. T cell immune function in tumor, skin and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin. Cancer Res. 2011, 17(17):5736-5747.

26. J.G. van den Boorn JG, C.J. Melief, R.M. Luiten. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res. 2011, 24(4):673-679.

25. J.G. van den Boorn, D.I. Picavet, P.F. van Swieten, H.A. van Veen, D. Konijnenberg, P.A. van Veelen, T. van Capel, E.C. de Jong, E.A. Reits, J.W. Drijfhout, J.D. Bos, C.J. Melief and R.M. Luiten. Skin-depigmenting agent monobenzone induces potent T cell autoimmunity towards pigmented cells by tyrosinase haptenation and melanosome autophagy. J. Invest Dermatol. 2011, 131(6):1240-51. 2011, in press. Featured on the issue cover, and as Editorial, J. Invest Dermatol. 2011, Jun;131(6):1185-7.

24. L. Nieuweboer-Krobotova en R.M. Luiten. Over immuungemedieerde dermatosen: Vitiligo: pathogenese, diagnose, behandeling en de relatie tot melanoom. Ondermeer 2010, 25: 3-12.

23. R.M. Luiten. Chemo-immunotherapie van kanker. Folia Pharmaceutica 2010, 98(1): 11-13.

22. J.G. van den Boorn, D. Konijnenberg, E.P.M. Tjin, D.I. Picavet, N.J. Meeuwenoord, D.V. Filippov, J.P.W. van der Veen, J.D. Bos, C.J.M. Melief, R.M. Luiten. Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG PloS ONE 2010, published 13 May 2010, [download article]

21. N.A. van Geel, I.G. Mollet, S. De Schepper, E.P.M. Tjin, K. Vermaelen, R.A. Clark, T.S. Kupper, R.M. Luiten, J. Lambert. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 2010; 23(3):375-384.

20. J.G. van den Boorn, D. Konijnenberg, T.A.M. Dellemijn, J.P. W. van der Veen, J.D. Bos, C.J.M. Melief, F.A. Vyth-Dreese and R.M. Luiten. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol, 2009, 129: 2220–2232.

19. R.M. Luiten. Vitiligo bij melanoom: verlichting van een woekering, Ned. Tijschr. Dermat. Venereol. 2009, 19(3):114-115.

18. K.U. Schallreuter, P. Bahadoran, M. Picardo, A. Slominski, Y.E. Elassiuty, E.H. Kemp, C. Giachino, J.B. Liu, R.M. Luiten, T. Lambe, I.C. Le Poole, I. Dammak, H. Onay, M.A. Zmijewski, M.L. Dell'Anna, M.P. Zeegers, R.J. Cornall, R. Paus, J.P. Ortonne and W. Westerhof. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Controversies in Experimental Dermatology, Experimental Dermatology 2008, 17(2): 139-140.

17. RM Luiten. Vitiligo bij melanoom: een gunstig teken. Nederlands Tijdschrift voor Oncologie 2006, jaargang 3, nr 6:224-230 [in pdf].

16. E.A. Reits, J.W. Hodge, C.A. Herberts, M. Chakraborty, E.K. Wansley, K. Camphausen, J. Schlom, R.M. Luiten, A de Ru, TA Groothuis, A Griekspoor, E Mesman, F Verreck, H Spits, P van Veelen, JJ Neefjes. Radiation modulates the peptide repertoire of MHC class I molecules and induces successful anti- tumor immunotherapy. J Exp Med, 2006; 203(5):1259-71.

15. J.G. van den Boorn, I.C. LePoole, R.M. Luiten. T cell avidity and tuning: the flexible connection between tolerance and autoimmunity. International Reviews of Immunology 2006;25(3-4):235-58.

14. K. Oyarbide-Valencia, J.G. van den Boorn, C. Denman, J. Carlson, C. Hernandez, M.I. Nishimura, P.K. Das, R.M. Luiten and I.C. Le Poole. Therapeutic implications of autoimmune vitiligo T cells. Autoimmunity Reviews 2006; 5(7):486-92.

13. RM Luiten, E.W.M. Kueter, W. Mooi, M.P.W. Gallee, E.M. Rankin, W.R. Gerritsen, S.M. Clift, W.J. Nooijen, P.Weder, W.F. van de Kasteele, J. Sein, P.C.M. van den Berk, O.E. Nieweg, A.M. Berns, H. Sptis and G.C. de Gast. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. Journal of Clinical Oncology. 2005; 23(35), [pdf] Featured as editorial by William E. Carson [in pdf]

12. N.C.V. Verra, A. Jorritsma, K. Weijer, J.J. Ruizendaal, A. Voordouw, P. Weder, E. Hooijberg, T.N.M. Schumacher, J.B.A.G. Haanen, H. Spits and R.M. Luiten. hTERT-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Research. 2004, 64:2153-2161. [pdf]

Cover blood11. A Röth, H Yssel, J Pène, EA Chavez, M Schertzer, PM Lansdorp, H Spits and RM Luiten. Telomerase levels control the lifespan of human T lymphocytes. Blood, 2003; 102(3): 849-57. [pdf] Featured as cover article

10. RM Luiten, J Pène, H Yssel and H Spits. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T cell clones and confers resistance to oxidative stress-induced apoptosis Blood. 2003; 101(11): 4512-9. [pdf]

9. Luiten RM, Demotte N, Tine J, van der Bruggen P. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens. 2000 Jul;56(1):77-81. [PubMed]

8. Luiten R, van der Bruggen P.A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens. 2000; 55(2):149-52. [PubMed]

7. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999; 163(5):2928-36. [pdf]

6. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999; 189(5):767-78. [pdf]

5. Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer. 1996; 74(5):735-44. [PubMed]

4. Luiten RM, Fleuren GJ, Warnaar SO, Litvinov SV. Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma associated antigen. Lab Invest. 1996; 74(2):467-75. [PubMed]

3. Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, Zurawski VR Jr, Coney LR. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J Immunother. 1997; 20(6):496-504. [PubMed]

2. Luiten RM, Warnaar SO, Schuurman J, Pasmans SG, Latour S, Daeron M, Fleuren GJ, Litvinov SV. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells. Hum Antibodies. 1997;8(4):169-80. [PubMed]

1. de Koster HS, Kenter MJ, D'Amaro J, Luiten RM, Schroeijers WE, Giphart MJ, Termijtelen A. Positive correlation between oligonucleotide typing and T-cell recognition of HLA-DP molecules. Immunogenetics. 1991;34(1):12-22. [PubMed]

Book Chapters

Jan D. Bos and Rosalie M. Luiten
Cancer Treatment and research series: Advances in cutaneous transplant oncology.
Chapter 1E: Skin Immune System (SIS).
E. Stockfleth, C. Ulrich, C. Proby, S. Euvrard, J.N. Bouwes-Bavink, Editors
Uitgever: Springer Science & Business Media, Inc.

Caroline Le Poole and Rosalie M. Luiten
Current Directions in Autoimmunity: Dermatologic Immunity
Chapter 12: Autoimmune etiology of generalized vitiligo
Drs. Brian J. Nickoloff and Frank O. Nestle, Editors
Dr. Argyrios N. Theofilopoulos, Series Editor
Uitgever: Basel, Karger Press, 2008, vol 10, pp1-17


4. W. Westerhof, R.M. Luiten, C.J.M. Melief. Sensitization of the immune systems against haptenized melanoma antigens. Patent nr. US 11/996,753 - EU 05769178.4 - CA 2,615,710 – AU 2005334836. Publication date: 2008-08-21

3. Chaux, R.M. Luiten, N. Demotte, M.T. Duffour, C. Lurquin, C. Traversari, V. Stroobant, G.R. Cornelis, T. Boon-Falleur, P. van der Bruggen, E Schultz and G. Warnier. Tumor antigens and CTL clones isolated by a novel procedure
(WO0020445, US2004185033, US6710172, US6531451, US6407063, JP2003518911T, EP1117679, AU5992999) [Espacenet.nl]

2. R.M. Luiten, T. Boon-Falleur, P. van der Bruggen, V. Stroobant, N. Demotte and E. Schultz. MAGE antigenic peptides, which bind HLA-B35 and B44
(WO0153833, US2002164654, EP1266221, AU2968101) [Espacenet.nl]

1. P. Chaux, T. Boon-Falleur, R.M. Luiten, C. Heirman, V. Stroobant, J. Corthals, K. Thielemans, P. van der Bruggen. MAGE-3 peptides presented by HLA Class II molecules.
(ZA9808124, WO9914326, US2003170792, US6716809, US6426217, US6369211, US6291430, US5965535, JP2002526110T, JP2001516579T, EP1119623, EP1012283, CA2303063, AU9306198, AU6042099, AU772720, AU757368) [Espacenet.nl]

Publications about my research

9. Breaking immunological tolerance to melanocyte differentiation antigens by hypopigmenting agents: a new means for melanoma immunotherapy? Becker JC, Schrama D. Editorial, J Invest Dermatol. 2011 Jun;131(6):1185-7.

8. Crème als immuuntherapie voor melanoom. Mednet 06, 2011: 38

7. Melanoombehandeling met crème (MI therapie). Melanoomnieuws Stichting Melanoom 2011; 13(2): 8-9.

6. Bleke huid tegen kanker. Melanoom: ziekte met ziekte bestrijden. AMC magazine May 2011; 5: 4-5. (Magazine of the Academic Medical Center, University of Amsterdam, The Netherlands).

5: A press release about the disseratation of my phd-student Jasper van den Boorn drew a lot of media attention. It was published in De Telegraaf (the biggest newspaper in the Netherlands), but also on a lot of newswebsites, like Nu.nl, Metro, Medicalfacts.nl, Gezondheidsnet.nl, Artsennet.nl, Zorg.nieuwslog, Folia.nl, Amsterdam Biomed and Drimble weblog. It also led to an interview on BNR Newsradio.

4. E. Gerritsma "De werkplek", Status, May 2007 (interview with R.M. Luiten)

3. J. Ekkelboom "Therapie met witte vlekken. Een kleurloos wapen tegen huidkanker", AMC magazine 3, 2006; 20-21.

2. W. Carson. "Getting melanoma cells to stimulate with frequency" Editorial, J. Clin. Oncol. 2005; 23(35): 8929-8931. [in pdf]

1. I. van Elsakker. "Witte vlekken tegen huidkanker", AMC magazine 2005; 5:30.

In addition, more than 5 press releases were published by the University of Leiden, Amsterdam and The Netherlands Organization of Scientific Research to announce the candidate as Laureate of the NWO-VIDI personal fellowship.

Other publications

8. "Meer succes met therapie voor vitiligo", Newsletter January 2006 of the LVVP (not online anymore), The Dutch Society of Vitiligo Patients

7. "Communicating European Research: the importance of explaining science to the public", Report of the EC conference CER2005 (Brussels, November 2005 ), MCFA website

6. "The Europe of Knowledge: a blueprint for competitive research in Europe", Report of EC conference Europe of Knowlegde 2020 (Liège, April 2004), MCFA website.

5. "Europe's hope: the strategy of togetherness", Report of the Thursday meeting of the EESC (Brussels, January 2006), MCFA website

4. MCFA Welcome Document for the Belgian MCFA Group, MCFA website

3. Minutes of the MCFA First National Co-ordinators meeting (London, June 1999).

2. Meeting of the Dutch national group.

1. Minutes of the first Belgian group meeting.

Rosalie Luiten has held more than 20 oral and poster presentations on the subject of cancer research, immunotherapy and gene therapy at international conferences, such as the Keystone symposia, Cancer Research Institute symposia and the European Society of Gene Therapy. She published the abstracts of these presentations in conference proceedings.

Delen |

. Ontwerp en realisatie: Nico van Dijk Media


Valid HTML 4.01 Transitional Valide CSS!